Call for Stronger Recommendations About Supplement Use During Chemotherapy
December 1st 1999The article by Drs. Labriola and Livingston is the first written collaboration of which I am aware between a doctor of naturopathic medicine and a professor of medicine at a major state university. The authors present a thorough review of the available information on interactions between dietary antioxidants, both natural and supplements, and chemotherapy.
Music Therapist Helps Cancer Patients Speak Through Song
December 1st 1999NEW YORK-The 24-year-old patient recuperating from a bone marrow transplant in a hospital room at Memorial Sloan-Kettering Cancer Center was depressed and not communicating. The staff thought Lucanne Magill, the hospital music therapist, could help.
Whole-Body Vibration Within Specified Frequency Range May Provide Pain Relief
December 1st 1999DENTON, Tex-Music has long been used, albeit unscientifically, to relax patients in an effort to relieve pain. Now, a researcher from the University of North Texas College of Music is attempting an approach to music therapy that involves vibration and appears to have a neurophysiologic mechanism of action.
Amifostine Reduces Acute and Chronic Xerostomia
December 1st 1999SAN ANTONIO -Pretreatment with amifostine (Ethyol) reduced the incidence of both acute and chronic xero-stomia in patients undergoing head and neck radiotherapy, David M. Brizel, MD, reported at the 41st Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO).
Pain Descriptions May Predict Presence of Neuropathic Pain
December 1st 1999BUFFALO, NY-Just by looking at the words cancer pain patients used to describe their pain, researchers were able to correctly predict in 66% of cases which patients had neuropathic pain, Dr. Thomas Sist, of the Roswell Park Cancer Institute, said in his poster presentation at the 8th World Congress on Pain.
Neurotoxicity Related to High-Dose Opioid Therapy Can Be Managed
December 1st 1999EDMONTON, Alberta-Vigorous worldwide pain education efforts emphasizing undertreatment have resulted in a "very healthy increase" in the use of opioids around the world, including increases in dose and length of exposure, Eduardo Bruera, MD, of the University of Alberta and Edmonton General Hospital, said at a plenary session of the 8th World Congress on Pain.
COX-2 Inhibitor Reduces Polyp Number in FAP Patients
December 1st 1999PHOENIX, Arizona-Drugs that inhibit cyclooxygenase-2 (COX-2) are the hottest thing in arthritis care this year and may have a role to play in combating colorectal cancer, according to a study presented at the American College of Gastroenterology 64th Annual Scientific Meeting.
Dr. Payne Urges Strategies to Overcome Barriers to Use of Cancer Pain Guidelines
December 1st 1999VANCOUVER, BC-The US Agency for Health Care Policy and Research (AHCPR) cancer pain practice guidelines, like the World Health Organization (WHO) 3-step ladder, emphasize a hierarchical pain management strategy, Richard Payne, MD, said at a symposium held in conjunction with the 8th World Congress on Pain of the International Association for the Study of Pain (IASP).
Program Trains Community Opinion Leaders in Principles of Pain Control
December 1st 1999DULUTH, Minn-Effective strategies to improve cancer pain management in the community may be elusive, but researchers from the Minnesota Cancer Pain Project, led by Thomas E. Elliott, MD, believe they are on the right track with an intervention program that combines education of community opinion leaders with community outreach programs.
Postmarketing Surveillance for Drug Abuse Supports Nonscheduled Status of Tramadol
December 1st 1999ST. LOUIS--When tramadol (Ultram) received FDA approval last year for use in moderate to moderately severe pain, its abuse potential was felt to be low (1.5 cases of abuse per 100,000 patients in the European experience).
First ‘Unconventional Innovations Program’ NCI Grants Awarded
December 1st 1999BETHESDA, Md-Researchers at five institutions have received the first contracts awarded by a new National Cancer Institute program intended to develop novel “one-stop” technologies capable of both detecting and destroying tumor cells. The five contracts, each of which is for 3 years, totaled nearly $11.3 million.
Renal Failure May Increase Need for Morphine Adjustment
December 1st 1999VIENNA, Austria-Cancer pain patients with chronic renal failure are more likely than others to need changes in their morphine regimen, reported M. Escher, MD, of the Multidisciplinary Pain Center, University Hospital, Geneva, Switzerland. This retrospective study, reported at the 9th World Congress on Pain, reviewed medical records of 110 cancer patients who had been referred for a pain consultation and had been prescribed morphine.
Women Are Replacing Old Breast Implants With New
December 1st 1999Results of a study conducted by the American Society of Plastic and Reconstructive Surgeons (ASPRS) showed that 84% of women who have had their breast implants removed have replaced them with new implants. In 1998, 32,262 women with breast augmentation had their breast implants removed, and 27,320 of them opted for new implants.
Consider Quality of Life and Patient Preference When Choosing Pain Relief
December 1st 1999SHEFFIELD, UK-What should the research question be when investigating a new approach to cancer pain? The most obvious answer is, Does it relieve pain? But David Brooks, MB, of the University of Sheffield, argues that this is not enough. Researchers must also ask about side effects, quality of life, and patient preference.
High-Dose Controlled-Release Oral Oxycodone Safety Reported
December 1st 1999VIENNA, Austria-Daily doses of controlled-release oral oxycodone (OxyContin, Oxygesic) exceeding 80 mg are as safe as lower doses when therapy is individualized, researchers from Purdue Pharma L.P. reported at the 9th World Congress on Pain.
Outcomes Data Are Essential for Pharmacoeconomic Evaluations
December 1st 1999VANCOUVER, BC-The use of pharmacoeconomics in cancer pain management is not about "decreasing the drug budget," but rather about evaluating the cost and outcomes of drug therapy, Stephen L. Huber, MS, RPh, said at a symposium held in conjunction with the 8th World Congress on Pain.
FTC Warns Against Home-Use Tests for HIV
December 1st 1999The Federal Trade Commission(FTC) released a consumer alert regarding home-use test kits for the human immunodeficiency virus (HIV). According to the FTC, some of the kits being marketed and sold on the Internet are giving users false information about their HIV status.
NCI Grants Establish 18 Biomarkers Developmental Laboratories
December 1st 1999BETHESDA, Md-Nearly $8 million in grants will help 17 organizations establish 18 Biomarkers Developmental Laboratories, part of the National Cancer Institute’s new Early Detection Research Network. The laboratories are charged with identifying, characterizing, and refining techniques for finding molecular, genetic, and biologic biomarkers.
Book Review:Wintrobe’s Clinical Hematology, 10th Edition
The 10th edition of Wintrobe’s Clinical Hematology is a two volume, multiauthored work that spans the ever-expanding discipline of hematology in over 2,600 pages. The book is appropriately introduced by an excellent short chapter written previously by Dr. Wintrobe on “The Diagnostic and Therapeutic Approach to Hematologic Problems.” There follows a valuable series of six chapters totaling 133 pages devoted to laboratory hematology, including blood and bone marrow examination, immunodiagnosis, clinical flow cytometry, cytogenetics, clusters of differentiation, and molecular genetics. These chapters contain ample illustrations, diagrams, tables, and references.
WHO Guidelines for Pediatric Cancer Pain Focus on Drug, Nondrug Strategies
December 1st 1999LONDON, Ontario-For a child with cancer, the pain related to the disease, its therapy, and required procedures is quite often the worst pain that the child has ever encountered, said Patricia A. McGrath, PhD, in her presentation at the World Health Organization workshop session on cancer pain.
Helping Patients Avoid Treatment-Related Nausea
December 1st 1999NEW YORK-Patients may talk about many treatment issues with their doctors but keep mum about treatment-related nausea. “When they go to their chemotherapy nurse, that’s when they say, ‘It was awful. I was sick for 3 days after chemotherapy,’” Terri Maxwell, RN, MSN, said at a teleconference sponsored by Cancer Care Inc.
Laptop Computer Allows Bedside Assessment of Pain and Automated Tracking of Medications
December 1st 1999HOUSTON-A male cancer patient receiving opioids for pain is reluctant to tell the female pain specialist at the clinic about his constipation until she hands him a small computer and shows him how to use a pen device to indicate his side effects from a list on the screen
New Drug Delivery Technology Improves Response Rate to Cytarabine
December 1st 1999Researchers at the University of California, San Diego, (UCSD) Cancer Center report success inusing a new technology to develop a sustained-release formulation of cytarabine (ara-C). The new formulation, called DepoCyt, produced a significantly better response rate than the standard ara-C formulation in patients with lymphomatous meningitis. Results of the open, multicenter, controlled study were reported at the 35th meeting of the American Society of Clinical Oncology (ASCO).
Use of Implanted Epidural Catheter for Opioid Delivery Appears Safe, Effective in Home Setting
December 1st 1999NEW YORK-An implanted epidural catheter can be a safe and effective means of providing analgesia in the home setting for patients with advanced cancer, Memorial Sloan-Kettering Cancer Center researchers found in a retrospective review.
WHO Adds More Opioids to its Analgesic Ladder for the Treatment of Cancer Pain
December 1st 1999MADISON, Wis--The World Health Organization (WHO), which first published its analgesic ladder in the original 1986 version of Cancer Pain Relief, has now issued an updated 2nd edition of the book that includes additional alternative opioids such as hydromorphone, oxycodone, and transdermal fentanyl, David E. Joranson, MSSW, said at the WHO workshop on cancer pain at the 8th World Congress on Pain.